Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.
Maria-Ioanna StefanouLina PalaiodimouAikaterini TheodorouMaria Veatriki ChristodoulouJohn S TzartosDimitrios TzanetakosDimitrios KitsosMaria ChondrogianniVasiliki ZouvelouEfthimios DardiotisElias TzavellasEkaterini SyrigouVassiliki BenetouGeorge P ParaskevasSotirios TsiodrasGeorgios TsivgoulisSotirios GiannopoulosPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
COVID-19 vaccination does not appear to increase the risk of relapse and serious adverse events in MS. Weighted against the risks of SARS-CoV-2-related complications and MS exacerbations, these safety data provide compelling pro-vaccination arguments for MS patients.
Keyphrases
- sars cov
- multiple sclerosis
- mass spectrometry
- coronavirus disease
- ms ms
- end stage renal disease
- respiratory syndrome coronavirus
- ejection fraction
- newly diagnosed
- chronic kidney disease
- white matter
- chronic obstructive pulmonary disease
- magnetic resonance
- prognostic factors
- peritoneal dialysis
- cystic fibrosis
- magnetic resonance imaging
- electronic health record
- computed tomography
- risk assessment
- big data
- network analysis
- deep learning